City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
Click here to login to Secure Web Site   (authorized users only)  
  
Search results:  103  Clinical trial(s) found  (Page 1 of 5 )
Results per page: 25 50 100 All 1-25 Trials Jump to page:

The following studies are available for :
COH Protocol Number: 16414 ClinicalTrials.gov Number: NCT03013933

Principal Investigator: Robert Chen, MD
Sponsor: Institutional

Title:  A Phase I Trial of Brentuximab Vedotin Plus MDR1 Inhibitors in Relapsed/Refractory Hodgkin Lymphoma

COH Protocol Number: 16408 ClinicalTrials.gov Number: NCT02959437

Principal Investigator: Marwan Fakih, MD
Sponsor: Industrial

Title:  A Phase 1/2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage IIIB or Stage IV Non–Small Cell Lung Cancer and Stage IV Microsatellite-Stable Colorectal Cancer

COH Protocol Number: 16368 ClinicalTrials.gov Number: NCT02953509

Principal Investigator: Leslie Popplewell, MD
Sponsor: Industrial

Title:  A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin’s Lymphoma

COH Protocol Number: 16346 ClinicalTrials.gov Number: NCT02568553

Principal Investigator: Jasmine Zain, MD
Sponsor: NCI Approved External Peer Review

Title:  PHI-79, NCI#9924: A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients with Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)

COH Protocol Number: 16318 ClinicalTrials.gov Number: NCT02760485

Principal Investigator: Robert Chen, MD
Sponsor: Industrial

Title:  An Open-Label Phase 1/2 Study of INCB039110 in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

COH Protocol Number: 16316 ClinicalTrials.gov Number: NCT02951156

Principal Investigator: Robert Chen, MD
Sponsor: Industrial

Title:  Phase 1b/Phase 3 Multicenter Study of Avelumab (MSB0010718c) in Combination Regimens that Include an Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DBCL)

COH Protocol Number: 16305 ClinicalTrials.gov Number: NCT02954796

Principal Investigator: Amrita Krishnan, MD
Sponsor: Industrial

Title:  Phase 1 Study of SGN-CD352A in Patients with Relapsed or Refractory Multiple Myeloma

COH Protocol Number: 16292 ClinicalTrials.gov Number: NCT02897765

Principal Investigator: Sumanta Pal, MD
Sponsor: Industrial

Title:  An Open-label, Phase IB Study of NEO-PV-01 + Adjuvant with Nivolumab in Patients with Melanoma, Non-Small Cell Lung Carcinoma or Transitional Cell Carcinoma of the Bladder

COH Protocol Number: 16279 ClinicalTrials.gov Number: NCT02926833

Principal Investigator: Alex Herrera, MD
Sponsor: Industrial

Title:  A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Combination with Atezolizumab in Subjects with Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

COH Protocol Number: 16277 ClinicalTrials.gov Number: NCT01897571

Principal Investigator: Leslie Popplewell, MD
Sponsor: Industrial

Title:  An Open-Label, Multicenter, Phase 1/2 Study of E7438 (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas

COH Protocol Number: 16273 ClinicalTrials.gov Number: NCT02890368

Principal Investigator: Christiane Querfeld, MD, PhD
Sponsor: Industrial

Title:  A Phase I Dose Escalation Trial of Intratumoral Injections of TTI-621 in Subjects with Relapsed and Refractory Percutaneously-Accessible Solid Tumors and Mycosis Fungoides

COH Protocol Number: 16272 ClinicalTrials.gov Number: NCT01822509

Principal Investigator: Alex Herrera, MD
Sponsor: NCI Approved External Peer Review

Title:  A Phase I/Ib Study of Ipilimumab or Nivolumab in Patients with Relapsed Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation

COH Protocol Number: 16260 ClinicalTrials.gov Number: NCT02864290

Principal Investigator: Monzr Al malki, MD
Sponsor: Industrial

Title:  A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS62P1 Given as Monotherapy in Subjects with Acute Myeloid Leukemia (AML)

COH Protocol Number: 16257 ClinicalTrials.gov Number: NCT02264613

Principal Investigator: Jasmine Zain, MD
Sponsor: Industrial

Title:  A Phase 1/2a Open-Label Study to Determine the Safety and Tolerability of ALRN-6924 in Patients with Advanced Solid Tumors or Lymphomas Expressing Wild-Type p53 Protein

COH Protocol Number: 16221 ClinicalTrials.gov Number: NCT03011814

Principal Investigator: Christiane Querfeld, MD, PhD
Sponsor: Institutional

Title:  A Phase 1/2 Trial of Durvalumab (MEDI4736) when Given as a Single Agent or in Combination with Lenalidomide in Patients with Relapsed/ Refractory Peripheral T-cell Lymphoma, Including Cutaneous T-cell Lymphoma

COH Protocol Number: 16215 ClinicalTrials.gov Number: NCT02030067

Principal Investigator: Vincent Chung, MD
Sponsor: Industrial

Title:  A Phase1, Open-Label, Dose-Ranging, Safety and Pharmacokinetic Study to Determine the Maximum Tolerated Dose of RX-3117 Administered Orally as a Single-Agent to Subjects with Advanced Malignancies

COH Protocol Number: 16211 ClinicalTrials.gov Number: NCT02892318

Principal Investigator: Samer Khaled, MD
Sponsor: Industrial

Title:  A Phase Ib Study Evaluating the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination with Immunomodulatory Agents in Patients with Acute Myeloid Leukemia

COH Protocol Number: 16210 ClinicalTrials.gov Number: NCT02508870

Principal Investigator: Samer Khaled, MD
Sponsor: Industrial

Title:  A Phase Ib Study of the Safety and Pharmacology of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) Administered Alone or in Combination with Azacitidine in Patients with Myelodysplastic Syndromes

COH Protocol Number: 16203 ClinicalTrials.gov Number: NCT02848248

Principal Investigator: Guido Marcucci, MD
Sponsor: Industrial

Title:  A Phase 1 Study of SGN-CD123A in Patient with Relapsed or Refractory Acute Myeloid Leukemia (AML)

COH Protocol Number: 16195 ClinicalTrials.gov Number: NCT02496663

Principal Investigator: Marianna Koczywas, MD
Sponsor: NCI Approved External Peer Review

Title:  PHI-77, NCI#9898: A Phase I Trial of AZD9291 and Necitumumab in EGFR-Mutant Non-Small Cell Lung Cancer after Progression on a Previous EGFR Tyrosine Kinase Inhibitor

COH Protocol Number: 16180 ClinicalTrials.gov Number: NCT02518113

Principal Investigator: Ibrahim Aldoss, MD
Sponsor: Industrial

Title:  A Phase 1b/Randomized Phase 2 Study to Evaluate LY3039478 in Combination with Dexamethasone in T-ALL/T-LBL Patients

COH Protocol Number: 16176 ClinicalTrials.gov Number: NCT02448251

Principal Investigator: Karen Reckamp, MD
Sponsor: Industrial

Title:  A Phase I/II, Multicenter, Open-label Safety, Pharmacokinetic and Preliminary Efficacy Study of Wild-type Sparing EGFR Inhibitor, AC0010MA, in Adult Patients with Previously Treated EGFRmut and Acquired T790M Mutation Non-Small Cell Lung Cancer (NSCLC)

COH Protocol Number: 16173 ClinicalTrials.gov Number: NCT02499328

Principal Investigator: Erminia Massarelli, MD, PhD
Sponsor: Industrial

Title:  A Phase 1b/2, Open-Label, Multicentre Study Assessing the Safety,Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

COH Protocol Number: 16163 ClinicalTrials.gov Number: NCT02268253

Principal Investigator: Haris Ali, MD
Sponsor: Industrial

Title:  SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

COH Protocol Number: 16159 ClinicalTrials.gov Number: NCT02520791

Principal Investigator: Jasmine Zain, MD
Sponsor: NCI Approved External Peer Review

Title:  PHI-85, NCI#9930: A Phase I Trial of MEDI-570 in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)

 
Results per page: 25 50 100 All 1-25 Trials Jump to page:

 
 
  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.